Current role
Biotechnology · Healthcare
Board Member
2019-01-01–present
Douglas S. Ingram
Board Member
Sarepta Therapeutics, Inc. (SRPT)Board Member
Relay Therapeutics, Inc. (RLAY)Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsAbout Douglas S. Ingram
Douglas S. Ingram is recorded as Board Member at Sarepta Therapeutics, Inc. (SRPT) since June 4, 2026 and Board Member at Relay Therapeutics, Inc. (RLAY) since January 1, 2019. The newest filing on record that lists Douglas S. Ingram as Board Member at Relay Therapeutics, Inc. (RLAY) is dated April 28, 2026. Sarepta Therapeutics, Inc. reported in an 8-K filed July 27, 2026 that Douglas S. Ingram resigned as membership on the Board of Directors of the Company, effective July 28, 2026. Sarepta Therapeutics, Inc. reported in an 8-K filed July 27, 2026 that Douglas S. Ingram retired as Chief Executive Officer, effective July 28, 2026. Sarepta Therapeutics, Inc. reported in an 8-K filed June 4, 2026 that Douglas S. Ingram was appointed director, effective June 4, 2026. The proxy statement of Sarepta Therapeutics, Inc. reports total compensation of $7,840,666 for Douglas S. Ingram in fiscal 2025, including a base salary of $1,171,425. Disclosed compensation is on record for 8 fiscal years. Relay Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Relay Therapeutics, Inc. includes Thomas Catinazzo (CFO), Brian R. Adams (General Counsel), Claire Mazumdar (Board Member) and 3 others.
“As of the Effective Date, Consultant has resigned from all officer and other positions with the Company and its affiliates, including his membership on the Board of Directors of the Company.”
“Consultant is retiring from his employment with the Company as its Chief Executive Officer ("Retirement") effective as of July 28, 2026 (the "Effective Date")”
Affiliation history
-
Current
2026-06-04–present
-
Current
2019-01-01–present
Last confirmed April 28, 2026
-
2026-06-04–2026-07-28
-
Start not stated–2026-07-28
Company network
Current role
Biotechnology · Healthcare
Board Member
2026-06-04–present
Leadership on record at Relay Therapeutics, Inc.
- Thomas Catinazzo CFO
- Brian R. Adams General Counsel
- Claire Mazumdar Board Member
- Habib Dable Board Member
- Lonnel Coats Board Member
- Sekar Kathiresan, M.D. Board Member
Leadership on record at Sarepta Therapeutics, Inc.
- Douglas Ingram CEO, Board Member
- Michael Severino, M.D. CEO, Board Member
- M. Kathleen Behrens Chairman
- Ryan H. Wong CFO
- Ian Estepan COO, Chief Accounting Officer
- Ian M. Estepan COO
- Cristin L. Rothfuss General Counsel
- Claude Nicaise Board Member
- Claude Nicaise, M.D. Board Member
- Deirdre Connelly Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sarepta Therapeutics, Inc. (SRPT) | Chief Executive Officer | $1,171,425 | $7,840,666 |
| 2024 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer | $846,902 | $1,978,086 |
| 2023 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer | $799,797 | $1,661,338 |
| 2022 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer | $740,025 | $124,938,694 |
| 2021 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer | $729,675 | $1,546,324 |
| 2020 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer ^^ | $669,250 | $1,291,947 |
| 2019 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer ^^ | $650,000 | $1,387,072 |
| 2018 | Sarepta Therapeutics, Inc. (SRPT) | President and Chief Executive Officer ^^ | $650,000 | $1,433,872 |